Clinical Trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.
Protocol Amendment History 1 change
notable Sponsor changed: Replimune Inc. -> Replimune, Inc. 2026-04-19
Trial Details
NCT Number NCT05733598
Lead Sponsor Replimune Inc.
Conditions Hepatocellular Carcinoma, Biliary Tract Cancer
Enrollment 60 participants
Start Date 2024-08-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-02